Journal article

Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-l-tyrosine on the TracerLab FXFN module

T Bourdier, I Greguric, P Roselt, T Jackson, J Faragalla, A Katsifis

Nuclear Medicine and Biology | Published : 2011

Abstract

Introduction: An efficient fully automated method for the radiosynthesis of enantiomerically pure O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) using the GE TracerLab FXFN synthesis module via the O-(2-tosyloxyethyl)-N-trityl-l-tyrosine tert-butylester precursor has been developed. Methods: The radiolabelling of [18F]FET involved a classical [18F]fluoride nucleophilic substitution performed in acetonitrile using potassium carbonate and Kryptofix 222, followed by acid hydrolysis using 2N hydrochloric acid. Results: [18F]FET was produced in 35±5% (n=22) yield non-decay-corrected (55±5% decay-corrected) and with radiochemical and enantiomeric purity of >99% with a specific activity of >90 GBq/μm..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

This study was funded by the Cooperative Research Centre for Biomedical Imaging Development, Ltd. (CRCBID), Bundoora, Victoria, Australia, established and supported under the Australian Government's Cooperative Research Centres program. Core academic partners of the CRC for Biomedical Imaging Development are as follows: the Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Height, NSW; the Garvan Institute of Medical Research, Darlinghurst, NSW; Monash University, Clayton, VIC; and the Peter MacCallum Cancer Centre, Melbourne, VIC; all in Australia. Core commercial partners are as follows: Berthold Australia Pty, Ltd., Bundoora, VIC; Cyclotek (Aust) Pty, Ltd., Bundoora, VIC, Australia; and GE Healthcare Pty, Ltd., Rydalmere, NSW, Australia.